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Abstract 
Background: Cognitive therapy, based on the Clark & Wells (1995) model, is a first-line treatment for adults 
with social anxiety disorder (SAD), and findings from research settings suggest it has promise for use with 
adolescents (Cognitive Therapy for Social Anxiety disorder in Adolescents; CT-SAD-A). However, for the 
treatment to be suitable for delivery in routine clinical care, two questions need to be addressed.  
Aims: Can therapists be trained to achieve good outcomes in routine Child and Adolescent Mental Health 
Services (CAMHS), and what are the costs associated with training and treatment.  
Methods: CAMHS therapists working in two NHS trusts received training in CT-SAD-A. They delivered the 
treatment to adolescents with SAD during a period of supervised practice. We examined the clinical outcomes 
for the 12 patients treated during this period, and estimated costs associated with treatment and training.  
Results: Treatment produced significant improvements in social anxiety symptoms, general anxiety and 
depression symptoms, and reductions in putative process measures. 75% (9 out of 12) patients showed a reliable 
and clinically significant improvement in social anxiety symptoms and 64% (7/11) lost their primary diagnosis 
of SAD. The total cost to the NHS of the CT-SAD-A treatment was £4047 (SD=1003) per adolescent treated, of 
which £1861 (SD=£358) referred to the specific estimated cost of face-to-face delivery; the remaining cost was 
for training and supervising therapists who were not previously familiar with the treatment. 
Conclusions: This study provides preliminary evidence that clinicians can deliver good patient outcomes for 
adolescents with SAD in routine CAMHS during a period of supervised practice after receiving a two-day 
training workshop. Furthermore, the cost of delivering CT-SAD-A with adolescents appeared to be no more 
















 Social anxiety disorder (SAD) is common and usually first occurs during adolescence (Kessler et al., 
2005; Merikangas, Nakamura, & Kessler, 2009), with almost all cases occurring by early adulthood (Beesdo, 
Pine, Lieb, & Wittchen, 2010). It is associated with high levels of impairment in education and work, social 
relationships, and day-to-day life (La Greca & Harrison, 2005; Ranta, Kaltiala-Heino, Rantanen, & Marttunen, 
2009; Stein & Kean, 2000; Wittchen, Fuetsch, Sonntag, Müller, & Liebowitz, 1999) and has a particularly low 
natural recovery rate in the absence of treatment (Bruce et al., 2005; Ranta et al., 2009). Developing effective 
and scalable treatments for adolescent SAD will be important to offset the individual, NHS and societal costs 
associated with the disorder. 
Cognitive therapy for SAD (CT-SAD) is a distinctive form of cognitive behavioural therapy (CBT) that 
is highly effective for adults (Mayo-Wilson et al., 2014). It aims to reverse the processes specified in the 
cognitive model of social anxiety developed by Clark and Wells (1995). Comparisons with other active 
treatments for adults have demonstrated that CT-SAD is superior to: two forms of group CBT, exposure 
therapy, interpersonal psychotherapy, psychodynamic psychotherapy, SSRIs, medication-focused treatment as 
usual, and placebo medication (Clark et al., 2006; Clark et al., 2003; Leichsenring et al., 2013; Mörtberg, Clark, 
Sundin, & Åberg Wistedt, 2007; Stangier, Heidenreich, Peitz, Lauterbach, & Clark, 2003; Stangier, Schramm, 
Heidenreich, Berger, & Clark, 2011). Individual CBT (including Clark & Wells’ CT-SAD) is recommended as 
the first-choice treatment for adult SAD in the current NICE Guideline (NICE, 2013), and was judged to be 
most cost-effective in the long-term. The Guideline noted the limited data for psychological interventions in 
youth SAD, and concluded that CBT was the most promising intervention, and further that CT-SAD should be 
considered for the treatment of adolescents with social anxiety. There is currently a lack of studies examining 
moderators of CBT for youth SAD, although for CBT in general, from the studies that have been carried out, it 
seems that factors such as modality and parental involvement may not affect response (Creswell, Waite, & 
Hudson, 2020).  
 In line with this, a randomised controlled trial with adolescents (Ingul, Aune, & Nordahl, 2014) 
demonstrated that CT-SAD was superior to both a psychological placebo and a generic form of CBT on self and 
clinician ratings at post-treatment. At 12-month follow-up when the two treatment arms were compared, it was 
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found that gains and group differences persisted. The study is significant as it demonstrates treatment specificity 
of cognitive therapy for SAD in adolescents. Whilst the findings are notable, CT-SAD was not implemented 
fully in the study. Interventions for socially traumatic memories were not included, and psychoeducation and 
anxiety hierarchies, which are not part of CT-SAD, were used. Subsequently, Leigh and Clark (2016) undertook 
a pilot study to examine whether the full CT-SAD could be delivered to adolescents with appropriate age-
relevant adaptation (Cognitive Therapy for Social Anxiety Disorder in Adolescents; CT-SAD-A). At the end of 
treatment, all participants were free of all diagnoses and this improvement was maintained at follow-up, with an 
average reduction of 87% on a social anxiety symptom scale. Taken together, these findings are promising and 
point to the potential value of delivering CT-SAD early in the course of social anxiety. However, the therapist in 
the pilot study had received extensive training in CT and we know from research with socially anxious adults 
that specific CT competencies are needed for good outcomes (Ginzburg et al., 2012). Therefore, the question 
arises as to whether modestly trained therapists in routine Child and Adolescent Mental Health Services 
(CAMHS) can also achieve good patient outcomes. This will be important to demonstrate if CT-SAD-A is to be 
disseminated more widely. Related to this, it is also necessary to estimate the NHS costs associated with training 
therapists and delivery of CT-SAD-A, as this can provide a first insight into the economic viability of the 
treatment in routine clinical practice.  
 The study had two main aims. First, to train NHS CAMHS therapists to deliver the adapted treatment 





Ethics and Consent 
The study was approved by the NHS South Central – Oxford B Research Ethics Committee (REC reference: 
16/SC/0315) and University of Reading Research Ethics Committee (UREC 16/43). Informed consent/assent 
was sought from parents and from young people. 
 
Treatment 
CT-SAD-A, which is the adolescent version of CT-SAD for adults based on the Clark and Wells (1995) model, 
is a distinctive form of CBT delivered in 14 weekly 1.5 hour sessions provided on a one-to-one basis. CT-SAD-
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A involves: development of an individualised version of the Clark & Wells (1995) model; an experiential 
exercise to help patients discover the unhelpful effects of self-focused attention and safety behaviours; video 
feedback; systematic training in externally focused, non-evaluative attention; and behavioural experiments. 
When indicated, there may also be work on: socially traumatic memories; anticipatory worry and post-event 
processing; low self-esteem; parental beliefs and behaviours; and bullying and its consequences. Further details 




The training employed a two-stage approach (Beidas & Kendall, 2010; Rakovshik & McManus, 2010) 
involving an initial workshop followed by a period of supervised practice. The two-day workshop involved a 
combination of teaching, video material, and experiential exercises and role-plays. Clinicians were provided 
with a detailed treatment manual and a memory stick containing extended training videos ahead of the workshop 
(these resources are available to access at www.oxcadatresources.com). After the workshop, clinicians attended 
weekly supervision via video-link or telephone in small groups. Supervision sessions involved detailed 
discussion of the previous treatment session, review of questionnaire measures, discussion of any problems that 
had arisen, and then step-by-step planning for the next session. Videotaped treatment sessions were discussed on 
a regular basis in supervision.  
  
Setting and Therapists 
Two NHS Foundation Trusts in England participated: Oxford Health and Berkshire Healthcare NHS Foundation 
Trusts. Seven therapists (four from Oxford Health) completed the training: three clinical psychologists and three 
CBT therapist. All had at least two years’ experience using CBT and of working with young people. One 
therapist attended the initial training workshop and three supervision sessions but then withdrew from the study 
due to a change in circumstances, therefore N=6 therapists for the report of clinical outcomes and N=7 therapists 
for cost outcomes.  
 
Inclusion and Exclusion Criteria for Adolescent Patients 
Young people (11-17.5 years) with a primary DSM-5 diagnosis of social anxiety disorder routinely referred to 
CAMHS were eligible. If young people were prescribed psychotropic medication the dosage must have been 
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stable for two months. Young people with established autistic spectrum disorders, learning disabilities, suicidal 
intent or recurrent self-harm, or identified by social services as currently ‘at risk’ due to child protection 
concerns were not eligible.  
 
Outcome Measures 
The Anxiety Disorders Interview Schedule (ADIS) – child and parent report (Silverman & Albano, 1996) was 
administered at baseline and follow-up to young people and parents by psychology postgraduates trained to a 
high level of inter-rater reliability (kappa/intraclass correlation was >.85 for diagnoses and Clinical Severity 
Ratings (CSR) across all anxiety disorders and for SAD specifically). For each disorder a CSR was assigned 
(from 0-8), with scores of 4 or more indicating presence of a disorder. 
The self-report version of the Liebowitz Social Anxiety Scale for Children and Adolescents (LSAS-CA-SR; 
Masia, Klein, & Liebowitz, 1999) assesses social anxiety. Fear and avoidance of 24 social situations are rated on 
a four-point scale (total range 0-144). It has well-established psychometric properties (Masia-Warner et al., 
2003). The Social Participation and Satisfaction Questionnaire (Alden & Taylor, 2011) assesses participation in 
and satisfaction with relationships. Concentration in class was assessed by asking young people to rate their 
ability to concentrate in class in the preceding week (0-100) (Leigh & Clark, 2016). Symptoms of anxiety and 
depression were assessed using the child version of the Revised Child Anxiety and Depression Scale (RCADS; 
Chorpita, Yim, Moffitt, Umemoto, & Francis, 2000). It has robust psychometric properties (Chorpita, Moffitt, & 
Gray, 2005).  
 
Process measures 
Several measures covering central processes in cognitive models of social anxiety (Clark et al., 2003) adapted 
for use with adolescents (Leigh & Clark, 2016) were used to guide therapy. The Child and Adolescent Social 
Summary Weekly Rating Scale (CASSWRS; Clark et al., 2003) was used as an additional measure of social 
anxiety, obtaining an average score (range 0-8). The Child and Adolescent Social Cognitions Questionnaire 
(CASCQ) covers 22 common social anxiety-related negative thoughts. A mean belief rating is obtained (range: 
0-100). The Child and Adolescent Social Attitudes Questionnaire (CASAQ) is a 41-item scale measuring social 
anxiety-related beliefs. A mean belief rating is obtained (range: 1-7). The Child and Adolescent Social 
Behaviour Questionnaire (CASBQ) is a 29-item scale of common social safety-seeking behaviours. A mean 
score is obtained (range: 0-3). All of these measures can be obtained from www.oxcadatresources.com  
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Treatment acceptability rating 
At the end of treatment, participants rated how acceptable they found the treatment (two items rated on a 5-point 
scale: ‘I was satisfied with the treatment’ and ‘I would recommend the treatment to others’). 
 
Health economic records 
Clinician Logs (Clinician includes both Supervisors and Therapists) were designed to capture the amount of 
healthcare resources (i.e. qualified staff time) necessary to implement CT-SAD-A. They were completed by 
both supervisors and therapists, who recorded the amount of time spent in activities related to the CT-SAD-A 
treatment, including training, supervision, preparation and delivery of CT-SAD-A.  Data recorded in the 
clinician’s logs was used to calculate the total mean amount of qualified staff time used by the NHS per 
adolescent treated. Results were stratified by type of staff time use. 
 
Analysis 
Comparisons between pre-treatment and follow-up were made with non-parametric Wilcoxon Signed Ranks 
tests. The Z statistic is presented, with associated p values and effect size estimates (r). An effect size of ≥0.1 is 
interpreted as small; ≥0.3 medium; and ≥0.5 is large (Cohen, 1988). Reliable change on our primary outcome 
measure, the LSAS-CA-SR, was defined as a pre–follow-up change exceeding the measurement error of the 
scale (Evans et al., 1998), based on data from Masia-Warner et al (2003), equating to a change of 16.13 or more. 
Reliable and clinically significant improvement (RCSI) was defined as pre-follow-up change of at least 2 
standard deviations (SDs) from the original mean (Evans et al., 1998), equating to a drop of at least 48.75 
points. 
 
In the cost analyses, for each study participant, all components of treatment costs, stratified by category of 
resource use, were computed by multiplying units of resource use by their unit costs (Curtis L. A., 2017) (see 
Supporting Information Table S1), expressed in 2016/17 UK pounds sterling (£). Mean imputation was used to 
handle missing data, as they referred to the time spent on face-to-face therapist contact with the young person, 
and were highly deterministic (i.e. readily identifiable and standardised given observed practice). A conditional 
imputation method was conducted whereby missing data were estimated as an average of known durations for 
the specific patient. Results were reported in terms of total amount of qualified staff time and associated NHS 
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costs for training and supervision as well as in terms of mean values of qualified staff time and associated NHS 




Characteristics of Patients 
The ten females and two males had an average age of 15.17 years (SD=1.80, range=12-17). The sample was 
predominantly White British (10/12), which was representative of the local areas. None reported being 
prescribed psychotropic medication. All met DSM-5 criteria for SAD. Only two patients had no comorbid 
diagnoses; GAD was present in eight patients, and depression (either MDD or dysthymia) in three.  There were 
five diagnoses of specific phobia pre-treatment across four patients, with one patient diagnosed with two 
specific phobias. One patient had a diagnosis of Posttraumatic Stress Disorder and one had a diagnosis of Panic 
Disorder. 
 
Seven patients received the planned 14 weekly therapy sessions, two patients received 10 weekly sessions, and 
one patient each received 11 sessions, 12 sessions, and 17 sessions. Seven patients received at least one booster 
session. The follow-up assessment was carried out on average 2.88 months (SD=1.15, range=1.16-4.63) after 
the final weekly therapy session.  
 
Outcomes 
<<Table 1 about here>> 
 
Social Anxiety Symptoms 
Table 1 presents baseline characteristics and social anxiety symptom outcomes at post-treatment and follow-up 
for patients. Treatment was associated with a significant reduction in social anxiety symptoms on the LSAS-
CA-SR at follow-up (Z = -3.06, p = .002, r = 0.62).  Scores dropped on average 66.80% over time (range: 3-
100%; Figure 1) and ten participants, 83% of the sample, made a reliable improvement. Nine of these 
participants also demonstrated a reliable and clinically significant improvement. RCADS social anxiety T-scores 
showed a significant and large decrease over treatment (Z =-2.93, p = .003, r = 0.60): eight patients were in the 
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borderline or clinical range at pretreatment, based on age and gender (T score > 65), whereas only one patient 
remained in the clinical range at follow-up.  
 
Diagnostic outcomes1 
Seven patients (64%) lost their primary diagnosis of SAD (see Table 1). Six lost their diagnosis of GAD, and 3 
diagnoses of specific phobia were lost (1 patient had 2 phobias at pre-treatment and lost one of these at follow-
up). Depressive disorders increased from 3 to 4 by follow-up. Of the four patients who retained their diagnosis 
of SAD at follow-up, one had lost their diagnosis of depression, two had retained their diagnosis of depression, 
and one had acquired a new diagnosis of depression. One patient lost their diagnosis of SAD but had become 
depressed at follow-up. Six patients (55%) were free of all diagnoses at follow-up.  
 
Other clinical outcomes 
As can be seen in Table 2, there was a significant drop in RCADS depression subscale scores1 over time (Z = -
2.94, p = .003, r = 0.63). For 10/11 patients, depression scores were below threshold (T<65) at follow-up (whilst 
5/11 had been below threshold pre-treatment). ID 4 continued to show elevated symptoms of depression at 
follow-up, and also developed a new diagnosis of depression over the course of treatment, whilst losing their 
SAD diagnosis (see diagnostic outcomes section). RCADS depression score for the other patient (ID 12) who 
had been assigned a new diagnosis of depression during the course of treatment was above threshold at the start 
of treatment and showed a small decrease at follow-up.  
 
There was a large and significant drop in RCADS GAD scores1 over the course of treatment, with all patients 
scoring below threshold at follow-up (Z = -3.02, p = .003, r = 0.64). The group as a whole showed large 
improvements in social participation (Z = -2.90, p = .004, r = 0.59) and moderate improvements at trend level in 
social satisfaction (Z = -1.96, p = .050, r = 0.40).  
 
The group showed a small to medium improvement in concentration (r = 0.30), although this was non-
significant (Z = -1.49, p = .137). As can be seen in Table 2, one young person showed no change (ID 10) and 
three a deterioration in their concentration (IDs 4, 11 and 12). Patients ID 10, 11, 12 are those young people who 
                                                     
1 Follow-up diagnostic, RCADS Depression and RCADS GAD data was missing for ID 11 and therefore N=11 
for these results. ID 11 had a comorbid diagnosis of GAD at baseline assessment.  
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did not show a clinically significant improvement on the LSAS-CA-SR and whilst ID 4 lost their diagnosis of 
SAD, they developed a new diagnosis of depression during treatment. 
 
Table 3 provides descriptive statistics for the process measures. All patients reported some reduction in ratings 
of belief in social cognitions and the group as a whole showed a large reduction in belief ratings on the CASCQ 
(Z = -3.06, p = .002, r = 0.62). For nine patients these reductions were substantial (belief rating reduced by 88-
100%), and these same patients also showed a clinically significant improvement on the LSAS-CA-SR. There 
was a large reduction in safety behaviour use by the end of treatment (Z = -2.85, p = .004, r = 0.58), and a large 
reduction in negative social attitudes (CASAQ) (Z = -2.67, p = .008, r = 0.55). Only one patient (ID10) showed 
a strengthening of their negative social attitudes, and they also retained their SAD diagnosis at follow-up.   
 
Treatment acceptability 
11 young people completed the treatment acceptability scale at the follow-up assessment. All of them agreed 
(either ‘somewhat’ or ‘completely’) with the statements ‘I was satisfied with the treatment’ and ‘I would 
recommend the treatment to others’. 
 
Cost of treatment delivery in NHS CAMHS  
Mean supervisor’s time per therapist attending each workshop was 278 minutes (SD=157) and associated mean 
NHS cost £287 (SD=162). Mean supervisor’s time per therapist per case supervision week was 50 minutes 
(SD=14) and associated mean NHS cost £51.5 (SD=14.6) (Table S2). Mean therapist’s time for each workshop 
attended was 420 minutes (7 hours) (SD=0) and associated mean NHS cost £294 (SD=0). On average, each 
therapist participated in 24 (SD=12) case supervision sessions. Mean therapist’s time per case supervision 
session attended was 73 minutes (SD=40) and associated mean NHS cost £51 (SD=28) (Table S3). Each 
adolescent treated received on average 5279 (around 88 hours) (SD=1301) of qualified clinician’s time 
(including therapist’s training and case supervision) and this would cost the NHS £4047 (SD=1003) per 
adolescent treated. The main cost driver was face-to-face delivery of the CT-SAD- Treatment (£1861; SD=358 
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The findings of the training case series provide preliminary evidence that good outcomes can be achieved from 
the delivery of CT-SAD-A in standard NHS CAMHS during supervised practice. Patients were routine referrals 
to CAMHS services. All patients presented with a primary diagnosis of SAD and received CT-SAD-A provided 
by CAMHS therapists as part of their training in this novel treatment. The group as a whole demonstrated large 
and significant improvements in social anxiety symptoms, as well as associated clinical outcomes. Substantial 
improvements in the proposed psychological mechanisms that are proposed to drive change in this treatment 
(social beliefs and behaviours) were also reported and treatment acceptability was high. To the best of our 
knowledge, this is the first detailed cost analysis of treatment for SAD in young people. The economic analysis 
indicated that the total cost to the NHS of the CT-SAD-A treatment was £4047 (SD=1003) per adolescent 
treated, of which £1861 (SD=£358) referred to the specific estimated cost of face-to-face delivery. The 
remaining cost was for training and supervising therapists who were not previously familiar with the treatment. 
 
As in the first case series of CT-SAD-A, undertaken by our group (Leigh & Clark, 2016), the drop in LSAS was 
substantial (67%) at follow-up. The mean change of 61 points on the LSAS reported here compares favourably 
with the figures reported for adult CT-SAD; e.g. mean changes of 43 and 46 on the LSAS reported by Clark and 
colleagues (2003 and 2006, respectively). From visual inspection of the LSAS-CA-SR (see Figure 1), it is clear 
that nine of the twelve patients reported considerable improvement in symptoms. They reported an average 
reduction of 85% on the measure (vs. 13% for the other three patients) and attained clinically significant 
improvement. Seven of the nine patients lost their primary SAD diagnosis and the other two showed reductions 
on their ADIS CSR SAD rating (ID 3: 7 to 4; ID 5: 7 to 5). All nine patients improved to below clinical 
thresholds on the social anxiety and GAD subscales of RCADS. These findings, and our loss of diagnosis rate of 
64% for the sample overall, compare favourably with outcomes of children and young people with SAD from 
trials of more general forms of CBT. For example, Ginsburg et al (2011) reported recovery rates of 40% among 
children and young people with SAD who received 14 sessions of a generic form of CBT for anxiety. 
 
Importantly, scores on measures of the psychological mechanisms that are targeted in CT-SAD-A all reduced 
substantially over the course of therapy for the nine improvers, in contrast to the non-improvers. On the 
CASCQ, the average reduction was 96% (89-100%) for the nine improvers vs. 32% (23-46%) for the 3 non-
improvers; on the CASBQ it was 77% (68-100%) vs. 7% (-3-25%); and on the CASAQ it was 43% (2-75%) vs. 
-4% (-48-22%).  
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Whilst we would not expect any treatment to be effective for all patients, it is interesting to consider why the 
three remaining patients responded considerably less well to therapy compared to the other nine. As can be seen 
from Figure 1, it does not appear to be a function of SAD severity. Possible explanations include factors relating 
to how the treatment was delivered. It may be that the particular therapists for these patients did not gain as 
much from the training as the others, or had less time available, so had less time to prepare, were less able to 
conduct full length sessions (90 minutes), and as such were less able to facilitate in vivo behavioural 
experiments. Alternatively, it might be that differences in therapist allegiance affected uptake and delivery of 
CT-SAD-A techniques. In future, examination of therapist allegiance ratings and blind rating of therapist 
competency could shed light on these hypotheses. Larger trials would provide the opportunity to examine 
potential predictors of response to treatment, including therapist and patient-specific factors, more thoroughly 
and systematically.  
 
Notably, the patient outcomes described are for those treated during the CAMHS therapists’ training, and so it is 
possible that the outcomes reported may be an underestimate of patients’ potential gains and an overestimate of 
economic costs, because we would expect therapists to achieve better outcomes as they accrue more experience.  
Future research would benefit from establishing the extent, and optimum modalities, for delivering therapist 
training in CT-SAD-A in order to achieve best outcomes. Notwithstanding these issues, the findings highlight 
the potential benefit of delivering CT-SAD to adolescents.  
 
There are, of course, important limitations of the training case series, including the small sample, which only 
included 2 males, and uncontrolled design lacking a baseline assessment phase, which means we cannot rule out 
the possibility of symptom change due to the passage of time, or non-specific therapy effects. We would suggest 
that this is unlikely, as the patients had all experienced symptoms for at least 6 months in order to qualify for a 
diagnosis, and in many cases social anxiety had been present for much longer. We cannot rule out potential non-
specific therapeutic benefits of therapist contact and support, and therefore a controlled comparison is needed to 
test this alternative explanation. Furthermore, longer term outcomes and examination of possible moderators of 
treatment outcomes should certainly be included in any further systematic evaluation. 
 
Delivering CT-SAD-A: A Clinical and Cost Analysis (FINAL ACCEPTED with proof edits) 
 14 
Strengths of the study included the thorough assessment and training procedures that were implemented within 
the CAMHS context. A further strength of our study is the inclusion of a cost analysis, highlighted as lacking by 
NICE (NICE, 2013). The estimated cost of delivering treatment (excluding training and supervision of 
therapists) was £1861 per young person treated within our study, which was admittedly based on a small sample 
size.  Nevertheless, in a tentative comparison with treatments for adults our cost compares favourably to NICE’s 
estimated cost of delivering CT-SAD per patient with adults (£2,341) (Mavranezouli et al., 2015), which has 
been found to be most cost-effective when psychological and pharmacological interventions for SAD adults 
have been compared (NICE, 2013).  
 
Our economic results need to be interpreted in light of some limitations. While the response rate of supervisor-
completed economic logs was 100% throughout the study duration, therapist-completed economics logs had 
rates of missing values that ranged from 50% to 67% for various treatment session across all patients, and 
imputation methods had to be used to handle missing data. Using mean imputation reduced sample variability 
with the consequence that uncertainty around our cost estimates was underestimated. It should also be noted that 
the way in which the training phase was conducted was less than optimal due to the fact that new therapists were 
recruited at different times throughout the training programme. Consequently, two cohorts of therapist were 
trained separately, causing a duplication of supervisors’ time in the training phase which led to inflated costs. In 
‘real world’ practice, workshops could be delivered to much larger numbers of therapists. This should be 
examined in future studies. Finally, the lack of a control condition precludes any conclusions about cost-
effectiveness (i.e. whether CT-SAD-A may be good value for money) in comparison to current usual practice.  
 
Our preliminary findings suggest that therapists working in busy CAMHS settings can achieve good outcomes 
for routinely referred SAD patients even whilst undergoing their training in the therapy and our results point to 
the potential value of delivering the training more widely. Based on our small sample and working within the 
current CAMHS context, the cost of delivering CT-SAD-A with adolescents appeared to be no more than the 
cost of delivering CT-SAD with adults, and would be expecting to bring greater economic advantages due to the 
earlier onset of benefits, including potentially related to increased engagement in education. 
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Table 1. Social anxiety symptom outcome measures  





Pre Post FU Pre FU Pre Post FU 
1 (1) 14 77 36 21 6 0 72.39 44.28 44.28 
2 (1) 14 123 40 28 6 0 81.92 46.28 46.28 
3 (2) 14 109 51 34 7 4 58.08 35.81 31.76 
4 (2) 14 105 49 20 6 3 59.46 39.46 39.46 
5 (3)  14 126 41 32 7 5 138.65 42.27 46.29 
6 (3) 14 87 2 0 4 0 68.20 25.69 29.74 
7 (4) 10 53 0 0 5 0 58.33 26.69 26.69 
8 (4) 12 94 5 8 7 0 74.40 30.22 30.22 
9 (5) 11 57 5 2 5 0 59.46 33.46 35.46 
10 (5) 14 137 65 103 7 8 74.40 44.28 58.08 
111 (6) 10 100 97 97 7 x 79.46 79.46 79.46 
12 (6)  17 100 103 89 7 7 66.37 56.33 60.34 
Median  100.09 40.50 24.50 6.50 0.00 70.30 40.87 41.89  

















Mean  97.41 41.17 36.18 6.17 2.45 74.26  42.02 44.00 
[SD]  [26.02] [35.08] [38.31] [1.03] [3.11] [21.93] [14.75] [15.58] 
Notes: Pre: Pre-treatment assessment; Post: Post-treatment assessment; FU: Follow up assessment; LSAS-CA-SR: Liebowitz Social Anxiety Scale – Child & Adolescent – Self-Report Version; ADIS SAD CSR: 
Anxiety Disorders Interview Schedule Social Anxiety Disorder Clinical Severity Rating; RCADS: Revised Children’s Anxiety & Depression Scale; SD: standard deviation; Q: Quartile. 
1 Participant 11 did not attend the follow-up assessment. Scores from their final weekly appointment are presented and included in follow-up summary statistics.  
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Pre FU Pre FU Pre FU Pre FU Pre FU 
1 (1) 14 53.69 37.96 51.37 37.90 80 95 52.00 63.00 14 22 
2 (1) 14 85.91 38.66 68.14 41.98 70 80 50.00 85.00 20 26 
3 (2) 14 78.41 47.72 51.84 29.68 50 50 23.00 46.00 15 20 
4 (2) 14 86.28 78.13 60.81 46.28 25 5 28.00 64.00 12 24 
5 (3)  14 93.89 44.7 72.94 35.20 0 40 21.00 39.19 10 10 
6 (3) 14 70.74 40.05 64.49 29.68 30 70 33.00 88.00 10 21 
7 (4) 10 37.06 31.57 39.81 30.25 60 100 64.00 91.00 22 28 
8 (4) 12 55.93 28.97 59.46 29.81 80 100 51.00 68.00 21 25 
9 (5) 11 59.1 45.52 55.00 37.56 70 80 54.00 55.00 19 10 
10 (5) 14 67.17 64.92 51.37 48.68 50 80 27.00 39.00 6 16 
111 (6) 10 x x x x 50 40 21.00 44.00 13 10 
12 (6)  17 64.92 62.67 56.77 51.37 75 60 51.00 42.00 16 13 
Median  67.17  44.70 56.77 37.56 55.00  65.00 41.50 59.00 14.50 20.50 





















Mean  68.46 47.35 57.46  38.04 53.33 64.17 39.58 60.35 14.83 18.75 
[SD]  [16.84] [15.18] [9.18] [8.07] [24.71] [28.73] [15.46] [19.38] [4.97] [6.69] 
Notes: Pre: Pre-treatment Assessment; FU: Follow up assessment; RCADS: Revised Children’s Anxiety & Depression Scale; SD: standard deviation; Q: Quartile. 
1 Participant 11 did not attend post-treatment assessment. Scores from their final weekly appointment are presented where available and included in follow-up summary statistics.  
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Table 3. Social anxiety process measures 
 






Pre FU Pre FU Pre FU Pre FU 
1 (1) 14 4.83 1.67 43.71 0.00 4.88 2.79 1.47 0.45 
2 (1) 12 6.67 0.83 83.23 3.87 6.27 2.63 2.24 0.55 
3 (2) 14 4.67 3.83 75.00 4.16 4.81 3.00 1.70 0.55 
4 (2) 14 5.67 0.67 70.29 2.58 4.69 2.54 1.27 0.33 
5 (3) 13 5.17 3.83 83.97 3.65 5.85 3.08 2.38 0.79 
6 (3) 14 5.67 0.50 67.10 7.67 4.87 1.21 1.79 0.24 
7 (4) 10 1.83 0.00 3.87 0.00 2.73 1.37 0.58 0.00 
8 (4) 12 4.83 0.17 44.19 1.29 2.54 2.48 1.33 0.24 
9 (5) 11 5.17 0.00 70.32 3.45 4.31 3.21 1.18 0.36 
10 (5) 14 6.20 5.00 84.84 61.83 2.60 3.87 1.94 2.00 
111 (6) 10 6.50 6.17 52.58 40.32 5.00 4.31 1.72 1.73 
12 (6) 14 5.67 3.83 63.87 34.52 4.96 3.85 1.97 1.48 
          
Median - 5.42 1.25 68.70 3.76  4.84 2.90 1.71 0.50 
















Mean - 5.24 2.21 61.91 13.61 4.46 2.86 1.63 0.73 
[SD] - [1.26] [2.19] [23.18] [20.32] [1.22] [0.93] [0.50] [0.65] 
Notes: Pre: Pre treatment Assessment; FU: Follow up assessment; CASSWRS: Adolescent Social Summary Weekly Rating Scale; CASCQ-B: Adolescent Social Cognitions Questionnaire Belief Ratings; CASAQ: 
Adolescent Social Attitudes Questionnaire; CASBQ: Adolescent Social Behaviour Questionnaire. 
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Figure 1. Individual patient LSAS-CA-SR scores at the following measurement points: preassessment, 
midtreatment, at the end of weekly sessions, and at the follow-up assessment. 
 
 
 
 
 
 
